CDK4 and head and neck squamous cell carcinoma: Whilst clinical trials utilizing CDK4/6 inhibitors are underway, this data suggests that a combination of CDK4/6 inhibitors such as palbociclib and abemaciclib with MEKi could be an effective strategy to overcome intrinsic resistance towards MEKi in HNSCC.